The Swiss biotech Polyphor is back with a fresh cautionary tale about the antibiotics sector.
Just days away from its first anniversary of an IPO $POLN that raised $165 million, the developer said late last week that it is halting enrollment in its pivotal trial of its antibiotic murepavadin for nosocomial pneumonia after investigators tracked high rates of acute kidney injury in their Phase III trial.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,